Once-yearly zoledronic acid in hip fracture prevention

Once-yearly zoledronic acid in hip fracture prevention

Oddom Demontiero, Gustavo DuqueAging Bone Research Program, Nepean Clinical School, University of Sydney, Penrith, NSW, Australia; Department of Geriatric Medicine, Nepean Hospital, Penrith, NSW, AustraliaAbstract: Osteoporosis is an escalating global problem. Hip fractures, the most catastrophic co...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Oddom Demontiero, Gustavo Duque
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2009
Materias:
zoledronic acid
osteoporosis
hip fractures
elderly
bisphosphonates
Geriatrics
RC952-954.6
Acceso en línea:https://doaj.org/article/a9df2c8fdb1b4560859e08926227e858
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:a9df2c8fdb1b4560859e08926227e858
record_format dspace
spelling oai:doaj.org-article:a9df2c8fdb1b4560859e08926227e8582021-12-02T02:44:57ZOnce-yearly zoledronic acid in hip fracture prevention1178-1998https://doaj.org/article/a9df2c8fdb1b4560859e08926227e8582009-03-01T00:00:00Zhttps://www.dovepress.com/once-yearly-zoledronic-acid-in-hip-fracture-prevention-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Oddom Demontiero, Gustavo DuqueAging Bone Research Program, Nepean Clinical School, University of Sydney, Penrith, NSW, Australia; Department of Geriatric Medicine, Nepean Hospital, Penrith, NSW, AustraliaAbstract: Osteoporosis is an escalating global problem. Hip fractures, the most catastrophic complication of osteoporosis, continue to cause significant mortality and morbidity despite increasing availability of effective preventative agents. Among these agents, oral bisphosphonates have been the first choice for the treatment and prevention of osteoporotic fractures. However, the use of oral bisphosphonates, especially in the older population, has been limited by their side effects and method of administration thus compromising their persistent use. The resultant low adherence by patients has undermined their full potential and has been associated with an increase in the incidence of fragility fractures. Recently, annual intravenous zoledronic acid (ZOL) has been approved for osteoporosis. Randomized controlled trials have demonstrated ZOL to be safe, have good tolerability and produce significant effect on bone mass and microarchitecture. Adherence has also been shown to be better with ZOL. Furthermore two large trials firmly demonstrated significant anti-osteoporotic effect (-59% relative risk reduction of hip fractures) and mortality benefit (28% reduction in mortality) of ZOL in older persons with recent hip fractures. In this review, we report the current evidence on the use of ZOL for the prevention of hip fractures in the elderly. We also report the pharmacological characteristics and the advantages and disadvantages of ZOL in this particular group.Keywords: osteoporosis, zoledronic acid, hip fracture, elderlyOddom DemontieroGustavo DuqueDove Medical Pressarticlezoledronic acidosteoporosiship fractureselderlybisphosphonatesGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 4, Pp 153-164 (2009)
institution DOAJ
collection DOAJ
language EN
topic zoledronic acid
osteoporosis
hip fractures
elderly
bisphosphonates
Geriatrics
RC952-954.6
spellingShingle zoledronic acid
osteoporosis
hip fractures
elderly
bisphosphonates
Geriatrics
RC952-954.6
Oddom Demontiero
Gustavo Duque
Once-yearly zoledronic acid in hip fracture prevention
description Oddom Demontiero, Gustavo DuqueAging Bone Research Program, Nepean Clinical School, University of Sydney, Penrith, NSW, Australia; Department of Geriatric Medicine, Nepean Hospital, Penrith, NSW, AustraliaAbstract: Osteoporosis is an escalating global problem. Hip fractures, the most catastrophic complication of osteoporosis, continue to cause significant mortality and morbidity despite increasing availability of effective preventative agents. Among these agents, oral bisphosphonates have been the first choice for the treatment and prevention of osteoporotic fractures. However, the use of oral bisphosphonates, especially in the older population, has been limited by their side effects and method of administration thus compromising their persistent use. The resultant low adherence by patients has undermined their full potential and has been associated with an increase in the incidence of fragility fractures. Recently, annual intravenous zoledronic acid (ZOL) has been approved for osteoporosis. Randomized controlled trials have demonstrated ZOL to be safe, have good tolerability and produce significant effect on bone mass and microarchitecture. Adherence has also been shown to be better with ZOL. Furthermore two large trials firmly demonstrated significant anti-osteoporotic effect (-59% relative risk reduction of hip fractures) and mortality benefit (28% reduction in mortality) of ZOL in older persons with recent hip fractures. In this review, we report the current evidence on the use of ZOL for the prevention of hip fractures in the elderly. We also report the pharmacological characteristics and the advantages and disadvantages of ZOL in this particular group.Keywords: osteoporosis, zoledronic acid, hip fracture, elderly
format article
author Oddom Demontiero
Gustavo Duque
author_facet Oddom Demontiero
Gustavo Duque
author_sort Oddom Demontiero
title Once-yearly zoledronic acid in hip fracture prevention
title_short Once-yearly zoledronic acid in hip fracture prevention
title_full Once-yearly zoledronic acid in hip fracture prevention
title_fullStr Once-yearly zoledronic acid in hip fracture prevention
title_full_unstemmed Once-yearly zoledronic acid in hip fracture prevention
title_sort once-yearly zoledronic acid in hip fracture prevention
publisher Dove Medical Press
publishDate 2009
url https://doaj.org/article/a9df2c8fdb1b4560859e08926227e858
work_keys_str_mv AT oddomdemontiero onceyearlyzoledronicacidinhipfractureprevention
AT gustavoduque onceyearlyzoledronicacidinhipfractureprevention
_version_ 1718402181966594048

Ejemplares similares